In vivo models and endpoints

To develop and evaluate preclinical models that detect pharmaceuticalinduced changes associated with i depression and ii suicidal ideation and behaviour especially in those behavioural domains which can be more readily assessed in animals such as anhedonia aggression and impulsivity iii in addition to possible cognitive impairment Perform proofofconcept in nonclinical models with pharmaceuticals known to induce such adverse effects in humans Evaluate the ability of nonclinical models across species to accurately predict pharmaceuticalinduced psychologicalpsychiatric changes in humans The following animal species will be considered Zebrafish rat and nonrodents Decision about the selection of the nonrodent species dog andor nonhuman primate will be influenced by the results obtained in rats Novel modelstests or sets of endpoints will need to be established with certain level of fitforpurpose validation conducted Special focus on specific brain areas will be considered as necessary